Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No officers or directors, no offices, nothing.
jmo
Its revoked too by Nevada SOS.
jmo
Sec named this Scam recently as a Scam.
jmo
EHYD ... what is the SEC going to do with this?? Delist??
American found dead on Grand Bahama was resident in Freeport – He was charged in US for Fraud!
Posted by media on Jan 28, 2014
http://www.bahamaspress.com/2014/01/28/american-found-dead-on-grand-bahama-was-resident-in-freeport-he-was-charged-in-us-for-fraud/
Man charged with fraud shows up dead at his home on Grand Bahama –
Freeport, Bahamas – Bahamas Press has learnt the white male found dead on Friday is indeed a man who has been Charged in a US Court for Fraud.
Grand Bahama police have identified the homicide victim as, Anthony Kyle Welch, age 47 years of #10 Albacore Drive and Mississippi, U.S.A. He was found dead in his home with multiple stab wound about the body and reported lifeless.
Bahamas Press can report that the US Securities commission have reported that: on August 31, 2012, the Securities and Exchange Commission filed a civil action in the United States District Court for the Northern District of Georgia against Anthony K. Welch, a former investment adviser formerly of Oxford, Mississippi, with securities fraud in conjunction with a series of false and misleading press releases issued in 2010 by eHydrogen Solutions, Inc. (“eHydrogen”) and ChromoCure, Inc. (“ChromoCure”), two now defunct microcap stock companies. Welch served as Chairman and Chief Executive Officer of the two companies during the relevant period and was responsible for the issuance of the false and misleading press releases of both companies. Welch at the time was based offshore, most recently in Freeport, Bahamas.
The Commission’s complaint alleges that from at least March 2010 through August 2010, Welch issued a series of press releases and made other public disclosures containing false and misleading information concerning, among other things, technologies acquired by and revenues generated by eHydrogen and ChromoCure. The complaint also alleges that the period of the false and misleading press releases coincided with suspicious price and trading volume increases in the common stock of eHydrogen and ChromoCure, and further alleged that in multiple instances such statements were intentionally false and misleading, distributed by Welch for no purpose other than to incite trading activity and artificially inflate the price and trading volume of eHydrogen and ChromoCure. For example, in a ChromoCure press release dated March 16, 2010, Welch stated among other things, “[t]he Company’s proprietary Chromosomal Scanner systems have proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company’s detection technology has been proven to have an effective accuracy of 100% for all cancers at all stages. This is superior to other detection approaches presently employed by pathologists, including biomarker detections, in every measurable way.” The same press release also stated that “[t]he Company’s detecting technology has an effective accuracy of 100% for all cancers at all stages.” The complaint alleges that this representation was false and misleading and that Welch and ChromoCure issued the statement without any reasonable basis for it, because in reality no 100% accurate cancer detection system is known to exist in the world.
Welch was found in a pool of blood with multiple stab wounds, a sliced throat and a finger cut off from each hand.
http://www.bahamaspress.com/2014/01/28/american-found-dead-on-grand-bahama-was-resident-in-freeport-he-was-charged-in-us-for-fraud/
Another Welch scam the SEC is watching.
jmo
Welch is on the run from the SEC on this one too.
jmo
Welch going by the name Goodwin now.
jmo
SEC Charges Former Mississippi Investment Adviser, Now Based in Bahamas, With Fraud
U.S. SECURITIES AND EXCHANGE COMMISSION
Litigation Release No. 22463 / August 31, 2012
SEC v. Anthony K. Welch, Civil Action No. 1:12-cv-3034 (ND Ga.)
SEC Charges Former Mississippi Investment Adviser, Now Based in Bahamas, With Fraud
On August 31, 2012, the Securities and Exchange Commission filed a civil action in the United States District Court for the Northern District of Georgia against Anthony K. Welch, a former investment adviser formerly of Oxford, Mississippi, with securities fraud in conjunction with a series of false and misleading press releases issued in 2010 by eHydrogen Solutions, Inc. (“eHydrogen”) and ChromoCure, Inc. (“ChromoCure”), two now defunct microcap stock companies. Welch served as Chairman and Chief Executive Officer of the two companies during the relevant period and was responsible for the issuance of the false and misleading press releases of both companies. Welch is now based offshore, most recently in Freeport, Bahamas.
The Commission’s complaint alleges that from at least March 2010 through August 2010, Welch issued a series of press releases and made other public disclosures containing false and misleading information concerning, among other things, technologies acquired by and revenues generated by eHydrogen and ChromoCure. The complaint also alleges that the period of the false and misleading press releases coincided with suspicious price and trading volume increases in the common stock of eHydrogen and ChromoCure, and further alleged that in multiple instances such statements were intentionally false and misleading, distributed by Welch for no purpose other than to incite trading activity and artificially inflate the price and trading volume of eHydrogen and ChromoCure. For example, in a ChromoCure press release dated March 16, 2010, Welch stated among other things, “[t]he Company’s proprietary Chromosomal Scanner systems have proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company’s detection technology has been proven to have an effective accuracy of 100% for all cancers at all stages. This is superior to other detection approaches presently employed by pathologists, including biomarker detections, in every measurable way.” The same press release also stated that “[t]he Company’s detecting technology has an effective accuracy of 100% for all cancers at all stages.” The complaint alleges that this representation was false and misleading and that Welch and ChromoCure issued the statement without any reasonable basis for it, because in reality no 100% accurate cancer detection system is known to exist in the world.
The Complaint alleges that Defendant Welch, by virtue of his conduct, directly or indirectly, has engaged and, unless enjoined, will engage in violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") [15 U.S.C. § 78j(b)] and Rule 10b-5 thereunder [17 C.F.R. § 240.10b-5]. Welch also has liability as a controlling person, pursuant to Section 20(a) of the Exchange Act for violations by eHydrogen and ChromoCure of Section 10(b) of the Exchange Act and Rule 10b-5(b) thereunder. Welch is alternatively charged herein with aiding-and-abetting the antifraud violations of eHydrogen and ChromoCure. The Commission seeks a permanent injunction against Welch for fraud, an accounting, disgorgement plus prejudgment interest, civil penalties, a penny stock bar and an officer and director bar.
SEC Complaint
http://www.sec.gov/litigation/complaints/2012/comp22463.pdf
http://www.sec.gov/litigation/litreleases/2012/lr22463.htm
EHYD will die an ungraceful death
jmo
Another Welch stock suspended.
jmo
Come on SEC .... put Welch behind bars.
jmo
Amazed the SEC has not delisted EHYD.
jmo
The SEC should delist this Welch fraud.
jmo
SEC Charges Former Mississippi Investment Adviser, Now Based in Bahamas, With Fraud
U.S. SECURITIES AND EXCHANGE COMMISSION
Litigation Release No. 22463 / August 31, 2012
SEC v. Anthony K. Welch, Civil Action No. 1:12-cv-3034 (ND Ga.)
SEC Charges Former Mississippi Investment Adviser, Now Based in Bahamas, With Fraud
On August 31, 2012, the Securities and Exchange Commission filed a civil action in the United States District Court for the Northern District of Georgia against Anthony K. Welch, a former investment adviser formerly of Oxford, Mississippi, with securities fraud in conjunction with a series of false and misleading press releases issued in 2010 by eHydrogen Solutions, Inc. (“eHydrogen”) and ChromoCure, Inc. (“ChromoCure”), two now defunct microcap stock companies. Welch served as Chairman and Chief Executive Officer of the two companies during the relevant period and was responsible for the issuance of the false and misleading press releases of both companies. Welch is now based offshore, most recently in Freeport, Bahamas.
The Commission’s complaint alleges that from at least March 2010 through August 2010, Welch issued a series of press releases and made other public disclosures containing false and misleading information concerning, among other things, technologies acquired by and revenues generated by eHydrogen and ChromoCure. The complaint also alleges that the period of the false and misleading press releases coincided with suspicious price and trading volume increases in the common stock of eHydrogen and ChromoCure, and further alleged that in multiple instances such statements were intentionally false and misleading, distributed by Welch for no purpose other than to incite trading activity and artificially inflate the price and trading volume of eHydrogen and ChromoCure. For example, in a ChromoCure press release dated March 16, 2010, Welch stated among other things, “[t]he Company’s proprietary Chromosomal Scanner systems have proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company’s detection technology has been proven to have an effective accuracy of 100% for all cancers at all stages. This is superior to other detection approaches presently employed by pathologists, including biomarker detections, in every measurable way.” The same press release also stated that “[t]he Company’s detecting technology has an effective accuracy of 100% for all cancers at all stages.” The complaint alleges that this representation was false and misleading and that Welch and ChromoCure issued the statement without any reasonable basis for it, because in reality no 100% accurate cancer detection system is known to exist in the world.
The Complaint alleges that Defendant Welch, by virtue of his conduct, directly or indirectly, has engaged and, unless enjoined, will engage in violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") [15 U.S.C. § 78j(b)] and Rule 10b-5 thereunder [17 C.F.R. § 240.10b-5]. Welch also has liability as a controlling person, pursuant to Section 20(a) of the Exchange Act for violations by eHydrogen and ChromoCure of Section 10(b) of the Exchange Act and Rule 10b-5(b) thereunder. Welch is alternatively charged herein with aiding-and-abetting the antifraud violations of eHydrogen and ChromoCure. The Commission seeks a permanent injunction against Welch for fraud, an accounting, disgorgement plus prejudgment interest, civil penalties, a penny stock bar and an officer and director bar.
SEC Complaint
http://www.sec.gov/litigation/complaints/2012/comp22463.pdf
http://www.sec.gov/litigation/litreleases/2012/lr22463.htm
welch abandoned this Scam ... the SEC is looking at it.
jmo
More likely the SEC delists EHYD.
jmo
im thinking we are going to see a move soon
With an SEC investigation ongoing??
lolol
jmo
Gonna add to streamer
Any update on the SEC's case concerning Welch?
jmo
EHYD is Dead ... the SEC is looking for CEO Welch.
jmo
Welch has totally disappeared.
RIP EHYD.
jmo
Oh no .. that doesn't sound good :(
NO .. some poor guy bought the wrong ticker.
jmo
up over 9800% today , must mean a R/S......
Welch is still on the RUN from the SEC.
jmo
Not a Peep from Welch or EHYD in over a year now.
jmo
welch pumped, dumped and went silent as usual.
Still the same ...
jmo
You can say that again.
lolol jmo
Ever since the SEC Hearing Request, Welch has been in hiding.
jmo
NO BID NO VOLUME ... rarely trades.
RIP EHYD.
Any news on the SEC Hearing into EHYD?
jmo
I agree ... there is no company and anthony welch is a bum.
Welch's antics are becoming bolder on his scams like EHYD.
jmo
Followers
|
23
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1439
|
Created
|
11/24/06
|
Type
|
Free
|
Moderators |
Current O/S 300,000,000. Float is 59,618,000. Share count maxed out as of 9/14/2009.
A/S 606,000,000 raised from 300,000,000 on 9/25/2009 filed with Nevada SOS
A/S increased to 8,000,000,000 on 10/06/09 per Nevada SOS.
Transfer Agent
PACIFIC STOCK TRANSFER COMPANY
4045 South Spencer Street, Suite 403
Las Vegas, NV 89119
Tel: (702) 361-3033
Fax: (702) 433-1979
ehydrogensolutions
5190 Neil Road - Suite 430
Reno, NV 89502
Phone: (775) 636-6077
(this is the Nevada Resident Agent's address and is not a physical office address for eHYD)
RECENT NEWS
http://ih.advfn.com/p.php?pid=news&symbol=EHYD
EHYD - Chart:
" rel="nofollow" target="_blank">http://stockcharts.com/c-sc/sc?s=EHYD&p=D&b=5&g=0&i=t68819328421&r=9843[/img]
Current Officers as of 10/2/2009:
ANTHONY K WELCH - Directors
ANTHONY K WELCH - President
ANTHONY K WELCH - Secretary/Treasurer
Anthony Welch lives in the Bahamas. eHYD has NO offices, employees or facilities.
Anthony K. Welch
Royal Palm way
22 Sea Grape Lane.
Lucaya, Freeport, Bahamas.
Company website: http://www.ehydrogensolutions.com/index.php?option=com_sfg&Itemid=10
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |